Scientists turn probiotic bacteria into tumor-hunting cancer killers

Researchers have successfully modified probiotic bacteria to function as targeted drug delivery systems that actively seek out cancerous growths. In animal studies, specifically involving mice, these engineered bacteria demonstrated the ability to infiltrate tumors and produce therapeutic anti-cancer drugs directly at the required site. This innovative, localized delivery method holds significant promise for enhancing treatment efficacy while simultaneously minimizing the systemic side effects often associated with conventional cancer therapies. Further extensive research and rigorous clinical trials are essential before this promising technology can be evaluated for potential application in human patients.